Anne Arens
German Cancer Research Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anne Arens.
Nature Biotechnology | 2011
Richard Gabriel; Angelo Lombardo; Anne Arens; Jeffrey C. Miller; Pietro Genovese; Christine Kaeppel; Ali Nowrouzi; Cynthia C. Bartholomae; Jianbin Wang; Geoffrey Friedman; Michael C. Holmes; Philip D. Gregory; Hanno Glimm; Manfred Schmidt; Luigi Naldini; Christof von Kalle
Zinc-finger nucleases (ZFNs) allow gene editing in live cells by inducing a targeted DNA double-strand break (DSB) at a specific genomic locus. However, strategies for characterizing the genome-wide specificity of ZFNs remain limited. We show that nonhomologous end-joining captures integrase-defective lentiviral vectors at DSBs, tagging these transient events. Genome-wide integration site analysis mapped the actual in vivo cleavage activity of four ZFN pairs targeting CCR5 or IL2RG. Ranking loci with repeatedly detectable nuclease activity by deep-sequencing allowed us to monitor the degree of ZFN specificity in vivo at these positions. Cleavage required binding of ZFNs in specific spatial arrangements on DNA bearing high homology to the intended target site and only tolerated mismatches at individual positions of the ZFN binding sites. Whereas the consensus binding sequence derived in vivo closely matched that obtained in biochemical experiments, the ranking of in vivo cleavage sites could not be predicted in silico. Comprehensive mapping of ZFN activity in vivo will facilitate the broad application of these reagents in translational research.
Cell Stem Cell | 2011
Sebastian M. Dieter; Claudia R. Ball; Christopher M. Hoffmann; Ali Nowrouzi; Friederike Herbst; Oksana Zavidij; Ulrich Abel; Anne Arens; Wilko Weichert; Karsten Brand; Moritz Koch; Jürgen Weitz; Manfred Schmidt; Christof von Kalle; Hanno Glimm
Human colon cancer harbors a small subfraction of tumor-initiating cells (TICs) that is assumed to be a functionally homogeneous stem-cell-like population driving tumor maintenance and metastasis formation. We found unexpected cellular heterogeneity within the TIC compartment, which contains three types of TICs. Extensively self-renewing long-term TICs (LT-TICs) maintained tumor formation in serial xenotransplants. Tumor transient amplifying cells (T-TACs) with limited or no self-renewal capacity contributed to tumor formation only in primary mice. Rare delayed contributing TICs (DC-TICs) were exclusively active in secondary or tertiary mice. Bone marrow was identified as an important reservoir of LT-TICs. Metastasis formation was almost exclusively driven by self-renewing LT-TICs. Our results demonstrate that tumor initiation, self-renewal, and metastasis formation are limited to particular subpopulations of TICs in primary human colon cancer. We identify LT-TICs as a quantifiable target for therapies aimed toward eradication of self-renewing tumorigenic and metastatic colon cancer cells.
Nature Medicine | 2009
Richard Gabriel; Ralph Eckenberg; Anna Paruzynski; Cynthia C. Bartholomae; Ali Nowrouzi; Anne Arens; Steven J. Howe; Claudia Cattoglio; Wei Wang; Katrin Faber; Kerstin Schwarzwaelder; Romy Kirsten; Annette Deichmann; Claudia R. Ball; Kamaljit S. Balaggan; Rafael J. Yáñez-Muñoz; Robin R. Ali; H. Bobby Gaspar; Luca Biasco; Alessandro Aiuti; Daniela Cesana; Eugenio Montini; Luigi Naldini; Odile Cohen-Haguenauer; Fulvio Mavilio; Aj Thrasher; Hanno Glimm; Christof von Kalle; William Saurin; Manfred Schmidt
Retroviral vectors have induced subtle clonal skewing in many gene therapy patients and severe clonal proliferation and leukemia in some of them, emphasizing the need for comprehensive integration site analyses to assess the biosafety and genomic pharmacokinetics of vectors and clonal fate of gene-modified cells in vivo. Integration site analyses such as linear amplification–mediated PCR (LAM-PCR) require a restriction digest generating unevenly small fragments of the genome. Here we show that each restriction motif allows for identification of only a fraction of all genomic integrants, hampering the understanding and prediction of biological consequences after vector insertion. We developed a model to define genomic access to the viral integration site that provides optimal restriction motif combinations and minimizes the percentage of nonaccessible insertion loci. We introduce a new nonrestrictive LAM-PCR approach that has superior capabilities for comprehensive unbiased integration site retrieval in preclinical and clinical samples independent of restriction motifs and amplification inefficiency.
Nature Protocols | 2010
Anna Paruzynski; Anne Arens; Richard Gabriel; Cynthia C. Bartholomae; Simone Scholz; Wei Wang; Stephan Wolf; Hanno Glimm; Manfred Schmidt; Christof von Kalle
High-throughput integration site profiling has become a feasible tool to assess vector biosafety and to monitor the cell fate of the gene-corrected cell population in clinical gene therapy studies. Here we report a step-by-step protocol for universal genome-wide and comprehensive integrome analysis that can be performed on >102–103 samples of interest in parallel. This assay is composed of fast and cost-efficient non-restrictive linear amplification–mediated PCR; optimized sample preparation for pyrosequencing; and automated bioinformatic data mining, including sequence trimming, alignment to the cellular genome and further annotation. Moreover, the workflow of this large-scale assay can be adapted to any PCR-based method aiming to characterize unknown flanking DNA adjacent to a known DNA region. Thus, in combination with next-generation sequencing technologies, large-scale integrome analysis of >4 × 105–1 × 106 integration site sequences can be accomplished within a single week.
Hepatology | 2011
Janka Matrai; Alessio Cantore; Cynthia C. Bartholomae; Andrea Annoni; Wei Wang; Abel Acosta-Sanchez; Ermira Samara-Kuko; Liesbeth De Waele; Ling Ma; Pietro Genovese; Martina Damo; Anne Arens; Kevin S. Goudy; Timothy C. Nichols; Christof von Kalle; Marinee Chuah; Maria Grazia Roncarolo; Manfred Schmidt; Thierry Vandendriessche; Luigi Naldini
Lentiviral vectors are attractive tools for liver‐directed gene therapy because of their capacity for stable gene expression and the lack of preexisting immunity in most human subjects. However, the use of integrating vectors may raise some concerns about the potential risk of insertional mutagenesis. Here we investigated liver gene transfer by integrase‐defective lentiviral vectors (IDLVs) containing an inactivating mutation in the integrase (D64V). Hepatocyte‐targeted expression using IDLVs resulted in the sustained and robust induction of immune tolerance to both intracellular and secreted proteins, despite the reduced transgene expression levels in comparison with their integrase‐competent vector counterparts. IDLV‐mediated and hepatocyte‐targeted coagulation factor IX (FIX) expression prevented the induction of neutralizing antibodies to FIX even after antigen rechallenge in hemophilia B mice and accounted for relatively prolonged therapeutic FIX expression levels. Upon the delivery of intracellular model antigens, hepatocyte‐targeted IDLVs induced transgene‐specific regulatory T cells that contributed to the observed immune tolerance. Deep sequencing of IDLV‐transduced livers showed only rare genomic integrations that had no preference for gene coding regions and occurred mostly by a mechanism inconsistent with residual integrase activity. Conclusion: IDLVs provide an attractive platform for the tolerogenic expression of intracellular or secreted proteins in the liver with a substantially reduced risk of insertional mutagenesis. (HEPATOLOGY 2011;)
Molecular Therapy | 2011
Hyoung Jin Kang; Cynthia C. Bartholomae; Anna Paruzynski; Anne Arens; Sujeong Kim; Seung Shin Yu; Youngtae Hong; Chang Wan Joo; Nam Kyung Yoon; Jung Woo Rhim; Joong Gon Kim; Christof von Kalle; Manfred Schmidt; Sunyoung Kim; Hyo Seop Ahn
X-linked chronic granulomatous disease (CGD) is an inherited immunodeficiency caused by a defect in the gp91(phox) gene. In an effort to treat X-CGD, we investigated the safety and efficacy of gene therapy using a retroviral vector, MT-gp91. Two X-CGD patients received autologous CD34(+) cells transduced with MT-gp91 after a conditioning regimen consisting of fludarabine and busulfan. The level of gene-marked cells was highest at day 21 (8.3 and 11.7% in peripheral blood cells) but decreased to 0.08 and 0.5%, respectively, 3 years after gene transfer. The level of functionally corrected cells, as determined by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase assay, reached a peak at day 17 (6.5% patient 1 (P1) and 14.3% patient 2 (P2) of total granulocytes) and declined to 0.05% (P1) and 0.21% (P2), 3 years later. Some retroviral vectors were found to have integrated within or close to the proto-oncogenes MDS1-EVI1, PRDM16, and CCND2; however, no abnormal cell expansion or related hematological malignancy was observed. Overall, the gene transfer procedure did not produce any serious adverse effects and was able to convert a significant fraction of blood cells to biologically functional cells, albeit for a short period of time.
Molecular Therapy | 2011
Cynthia C. Bartholomae; Anne Arens; Kamaljit S. Balaggan; Rafael J. Yáñez-Muñoz; Eugenio Montini; Steven J. Howe; Anna Paruzynski; Bernhard Korn; Jens Uwe Appelt; Angus MacNeil; Daniela Cesana; Ulrich Abel; Hanno Glimm; Luigi Naldini; Robin R. Ali; Adrian J. Thrasher; Christof von Kalle; Manfred Schmidt
Lentiviral vectors with self-inactivating (SIN) long terminal repeats (LTRs) are promising for safe and sustained transgene expression in dividing as well as quiescent cells. As genome organization and transcription substantially differs between actively dividing and postmitotic cells in vivo, we hypothesized that genomic vector integration preferences might be distinct between these biological states. We performed integration site (IS) analyses on mouse dividing cells (fibroblasts and hematopoietic progenitor cells (HPCs)) transduced ex vivo and postmitotic cells (eye and brain) transduced in vivo. As expected, integration in dividing cells occurred preferably into gene coding regions. In contrast, postmitotic cells showed a close to random frequency of integration into genes and gene spare long interspersed nuclear elements (LINE). Our studies on the potential mechanisms responsible for the detected differences of lentiviral integration suggest that the lowered expression level of Psip1 reduce the integration frequency in vivo into gene coding regions in postmitotic cells. The motif TGGAA might represent one of the factors for preferred lentiviral integration into mouse and rat Satellite DNA. These observations are highly relevant for the correct assessment of preclinical biosafety studies, indicating that lentiviral vectors are well suited for safe and effective clinical gene transfer into postmitotic tissues.
Human Gene Therapy Methods | 2012
Anne Arens; Jens Uwe Appelt; Cynthia C. Bartholomae; Richard Gabriel; Anna Paruzynski; Derek Gustafson; Nathalie Cartier; Patrick Aubourg; Annette Deichmann; Hanno Glimm; Christof von Kalle; Manfred Schmidt
Clonality analysis of viral vector-transduced cell populations represents a convincing approach to dissect the physiology of tissue and organ regeneration, to monitor the fate of individual gene-corrected cells in vivo, and to assess vector biosafety. With the decoding of mammalian genomes and the introduction of next-generation sequencing technologies, the demand for automated bioinformatic analysis tools that can rapidly process and annotate vector integration sites is rising. Here, we provide a publicly accessible, graphical user interface-guided automated bioinformatic high-throughput integration site analysis pipeline. Its performance and key features are illustrated on pyrosequenced linear amplification-mediated PCR products derived from one patient previously enrolled in the first lentiviral vector clinical gene therapy study. Analysis includes trimming of vector genome junctions, alignment of genomic sequence fragments to the host genome for the identification of integration sites, and the annotation of nearby genomic elements. Most importantly, clinically relevant features comprise the determination of identical integration sites with respect to different time points or cell lineages, as well as the retrieval of the most prominent cell clones and common integration sites. The resulting output is summarized in tables within a convenient spreadsheet and can be further processed by researchers without profound bioinformatic knowledge.
Molecular Therapy | 2011
Annette Deichmann; Martijn H. Brugman; Cynthia C. Bartholomae; Kerstin Schwarzwaelder; Monique M.A. Verstegen; Steven J. Howe; Anne Arens; Marion Ott; Dieter Hoelzer; Reinhard Seger; Manuel Grez; Salima Hacein-Bey-Abina; Marina Cavazzana-Calvo; Alain Fischer; Anna Paruzynski; Richard Gabriel; Hanno Glimm; Ulrich Abel; Claudia Cattoglio; Fulvio Mavilio; Barbara Cassani; Alessandro Aiuti; Cynthia E. Dunbar; Christopher Baum; H. Bobby Gaspar; Adrian J. Thrasher; Christof von Kalle; Manfred Schmidt; Gerard Wagemaker
Vector-associated side effects in clinical gene therapy have provided insights into the molecular mechanisms of hematopoietic regulation in vivo. Surprisingly, many retrovirus insertion sites (RIS) present in engrafted cells have been found to cluster nonrandomly in close association with specific genes. Our data demonstrate that these genes directly influence the in vivo fate of hematopoietic cell clones. Analysis of insertions thus far has been limited to individual clinical studies. Here, we studied >7,000 insertions retrieved from various studies. More than 40% of all insertions found in engrafted gene-modified cells were clustered in the same genomic areas covering only 0.36% of the genome. Gene classification analyses displayed significant overrepresentation of genes associated with hematopoietic functions and relevance for cell growth and survival in vivo. The similarity of insertion distributions indicates that vector insertions in repopulating cells cluster in predictable patterns. Thus, insertion analyses of preclinical in vitro and murine in vivo studies as well as vector insertion repertoires in clinical trials yielded concerted results and mark a small number of interesting genomic loci and genes that warrants further investigation of the biological consequences of vector insertions.
Nature Communications | 2015
Eliana Ruggiero; Jan P. Nicolay; Raffaele Fronza; Anne Arens; Anna Paruzynski; Ali Nowrouzi; Gökçe Ürenden; Christina Lulay; Sven Schneider; Sergij Goerdt; Hanno Glimm; Peter H. Krammer; Manfred Schmidt; Christof von Kalle
Unbiased dissection of T-cell receptor (TCR) repertoire diversity at the nucleotide level could provide important insights into human immunity. Here we show that TCR ligation-anchored-magnetically captured PCR (TCR-LA-MC PCR) identifies TCR α- and β-chain diversity without sequence-associated or quantitative restrictions in healthy and diseased conditions. TCR-LA-MC PCR identifies convergent recombination events, classifies different stages of cutaneous T-cell lymphoma in vivo and demonstrates TCR reactivation after in vitro cytomegalovirus stimulation. TCR-LA-MC PCR allows ultra-deep data access to both physiological TCR diversity and mechanisms influencing clonality in all clinical settings with restricted or distorted TCR repertoires.